Literature DB >> 8135186

Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease.

G F Hodges1, T M Lenhardt, J D Cotelingam.   

Abstract

Discordant lymphomas are those in which two different histologic subtypes of non-Hodgkin's lymphoma are present simultaneously in the same patient at two or more separate disease sites. Discordance usually involves a lower grade follicular lymphoma in one anatomic site and a higher grade diffuse lesion elsewhere. A common type of discordance is seen in patients with a primary diagnosis of diffuse large-cell lymphoma (DLCL) who demonstrate bone marrow involvement by a lower grade lesion, such as a small cleaved cell or mixed small cleaved and large cell lymphoma. This study was undertaken to assess retrospectively the clinical implications of such bone marrow involvement, as well as the possible biologic mechanisms. Of the 59 DLCL cases studied, 20 (33.9%) showed evidence of bone marrow involvement, 14 of which were discordant (70%). The most significant findings included the following: Overall treatment responses and survivals in discordant patients with predominantly small cleaved cells in the marrow were similar to those in patients with no marrow involvement (mean survivals, 47.7 and 49 months, respectively), and were significantly longer than in patients with concordant marrow involvement (mean survival, 13.1 months, P < .05). Patients with discordant marrow infiltrates composed of a mixed cell population tended to do as poorly as those with concordant involvement. No clear-cut pattern of relapse in discordant patients was found, but persistence of small cleaved cells in some was reminiscent of lower grade B-cell lesions. Other features associated with lower grade lesions included older age, less incidence of central nervous system involvement, and lesser extent and proportion of marrow infiltration. Finally, in approximately half the cases with discordant involvement, lymphoma was present unilaterally, emphasizing the need to perform bilateral biopsies for staging.

Entities:  

Mesh:

Year:  1994        PMID: 8135186     DOI: 10.1093/ajcp/101.3.305

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

Review 1.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

2.  Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).

Authors:  Magdalena Adde; Gunilla Enblad; Hans Hagberg; Christer Sundström; Anna Laurell
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas.

Authors:  Deborah W Sevilla; Erin M Weeden; Suzy Alexander; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  Virchows Arch       Date:  2009-10-06       Impact factor: 4.064

4.  Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type.

Authors:  Anne M Tierens; Harald Holte; Abdirashid Warsame; Ida M Ikonomou; Junbai Wang; Wing C Chan; Jan Delabie
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

5.  High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.

Authors:  Moo-Kon Song; Joo-Seop Chung; Je-Jung Lee; Deok-Hwan Yang; In-Suk Kim; Dong-Hoon Shin; Ho-Jin Shin
Journal:  Int J Hematol       Date:  2014-12-12       Impact factor: 2.490

6.  Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Authors:  Z Yao; L Deng; Z Y Xu-Monette; G C Manyam; P Jain; A Tzankov; C Visco; G Bhagat; J Wang; K Dybkaer; W Tam; E D Hsi; J H van Krieken; M Ponzoni; A J M Ferreri; M B Møller; J N Winter; M A Piris; L Fayad; Y Liu; Y Song; R Z Orlowski; H Kantarjian; L J Medeiros; Y Li; J Cortes; K H Young
Journal:  Leukemia       Date:  2017-07-12       Impact factor: 11.528

7.  Evaluation of B cell lymphoid infiltrates in bone marrow biopsies by morphology, immunohistochemistry, and molecular analysis.

Authors:  B Maes; R Achten; A Demunter; B Peeters; G Verhoef; C De Wolf-Peeters
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

8.  Lack of utility of CD20 immunohistochemistry in staging bone marrow biopsies for diffuse large B-cell lymphoma.

Authors:  Daniel Baiyee; Roger Warnke; Yasodha Natkunam
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-03

9.  Leukemic presentation with discordant morphology in triple-hit lymphoma-A diagnostic pitfall during COVID-19 pandemic.

Authors:  Debadrita Ray; Nabhajit Mallik; Sreejesh Sreedharanunni; Arihant Jain; Amanjit Bal; Man Updesh Singh Sachdeva
Journal:  Int J Lab Hematol       Date:  2021-06-04       Impact factor: 3.450

10.  Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Min-Chul Cho; Yousun Chung; Seongsoo Jang; Chan-Jeoung Park; Hyun-Sook Chi; Jooryung Huh; Cheolwon Suh; Hyoeun Shim
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.